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Objective: To evaluate the effect of a human-bovine reassortant pentavalent rotavirus vaccine
(PRV) on health care encounters in nearly 70 000 subjects randomized in three regions --- Europe,
the United States, and Latin America/the Caribbean --- in the Rotavirus Efficacy and Safety Trial
(REST).
Methods: Healthy 6- to 12-week-old infants received 3 doses of PRV or placebo at 4- to 10-week
intervals. The exact binomial method for ratios of Poisson counts was used to evaluate the
effect of PRV on the rate of rotavirus-related hospitalizations and emergency department (ED)
visits involving rotavirus G-types 1---4 occurring ≥14 days after the third dose of vaccine for up
to 2 years.
Results: In fully vaccinated infants, reductions in rotavirus-associated hospitalizations and ED
visits were 94.7% (95% CI: 90.9, 96.9) in Europe, 94.9% (95% CI: 84.0, 98.9) in the United States,
and 90.0% (95% CI: 29.4, 99.8) in the Latin American/Caribbean regions.
Conclusions: PRV reduced hospitalizations and ED visits within each region in REST. Results were
consistent across regions and across the overall study cohort.
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* Address correspondence and reprint requests to: Timo Vesikari,
MD, University of Tampere Medical School, Department of Pe-
diatrics, Virology/Vaccine Research Centre, Finn-Medi 3, 33014
Tampere, Finland. Tel.: +358-3-3551-8444; Fax: +385-3-3551-8450.
E-mail address: timo.vesikari@uta.fi
1201-9712/$32.00 © 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Introduction
Rotavirus gastroenteritis is an important cause of morbidity
and mortality worldwide, resulting in more than 600 000
deaths, 2.3 million hospitalizations, and 24 million outpa-
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tient visits among infants and young children each year.1
Rotaviruses infect nearly all infants by 5 years of age
regardless of socioeconomic status or country of birth and
there is no method to reliably predict which infants will
experience a more severe course of illness.2 Recently, the
New England Journal of Medicine reported the results of
the Rotavirus Efficacy and Safety Trial (REST), a large-scale
Phase III clinical trial demonstrating the safety and effi-
cacy of a pentavalent human-bovine reassortant rotavirus
vaccine expressing human rotavirus G-types G1, G2, G3,
and G4, and P type P1A[8] (PRV [pentavalent rotavirus
vaccine], RotaTeq™, Merck & Co., Inc., Whitehouse Station,
New Jersey, USA).3
The large study population in REST provided the oppor-
tunity to evaluate the efficacy of the vaccine in reducing
rotavirus-associated health care resource utilization dur-
ing the trial, i.e., hospitalizations, emergency department
(ED) visits, which can be considered a surrogate for severe
disease, and office visits for rotavirus gastroenteritis. Over-
all, among the 28 646 subjects in the vaccine group and 28
488 subjects in the placebo group who comprised the per-
protocol analysis in which all infants were fully vaccinated
(i.e., received 3 doses), PRV reduced the incidence of
hospitalizations and ED visits for rotavirus gastroenteritis
caused by serotypes G1, G2, G3, and G4 occurring 14 or
more days after the completion of the 3-dose series for
up to 2 years by 94.5% (95% CI: 91.2, 96.6). Individually,
the rate of hospitalizations was reduced by 95.8% (95% CI:
90.5, 98.2) and the rate of ED visits was reduced by 93.7%
(95% CI: 88.8, 96.5).
Among a subset of 2173 subjects in the vaccine group
and 2278 subjects in the placebo group in which effi-
cacy against rotavirus gastroenteritis of any severity was
evaluated (efficacy subset), PRV reduced office visits for
rotavirus gastroenteritis caused by serotypes G1, G2, G3,
and G4 in fully vaccinated children for up to 2 years after
vaccination by 86% (95% CI: 73.9, 92.5).
The REST study was conducted in 11 countries repre-
senting 3 regions with different populations and health
care delivery systems --- Europe, the United States, and
Latin America/the Caribbean. Historically, the efficacy
of rotavirus vaccines has varied according to geographic
region, generally demonstrating reduced efficacy in less
developed areas.1,4 Here we report the efficacy of PRV in
reducing health care utilization associated with episodes
Figure 1 Enrollment in the Rotavirus Efficacy and Safety Trial by
country.
of rotavirus gastroenteritis in these 3 regions. The par-
ticipating countries in Europe included Finland, Germany,
Belgium, Sweden, and Italy and in the Latin Ameri-
can/Caribbean region, Jamaica, Costa Rica, Mexico, and
Guatemala. Although a self-governing island that is part of
the commonwealth of the United States, Puerto Rico was
included in the Latin American/Caribbean region for these
analyses (Figure 1). Taiwan was excluded from the analysis
because health care utilization was not reported from this
country.
Methods
A complete description of the study methodology of
REST has been published previously.3 REST was a blinded,
placebo-controlled, randomized trial conducted from 2001
to 2004. Healthy infants 6 to 12 weeks of age were
randomized to receive 3 oral doses of PRV or placebo
at 4- to 10-week intervals. Active surveillance for hos-
pitalizations and ED visits for gastroenteritis was to be
conducted on Days 7, 14, and 42 after each dose and
every 6 weeks thereafter via telephone contact. Subjects
in the safety subset were to be followed for 365 days
after the first dose. In a subset of subjects in Finland, the
United States, and Puerto Rico (efficacy subset), efficacy
against rotavirus gastroenteritis of any severity (ie, all
episodes) was evaluated. Subjects in this subset also were
to be contacted on Days 7, 14, and 42 after each dose
and then more frequently thereafter via telephone (i.e.,
every 2 weeks during the rotavirus season). All health
care encounters for gastroenteritis, including office visits,
were to be documented for these subjects. The subjects
in the efficacy subset were followed for a maximum of 2
years. The duration of follow up was dependent on when
the infants were enrolled in the study in relation to the
rotavirus season defined in the protocol. If the infant was
enrolled in the midst of the rotavirus season, the infant
was followed until the end of the next rotavirus season.
The case definition for rotavirus gastroenteritis required
that subjects meet both clinical and laboratory criteria.
The clinical criterion was the occurrence of 3 or more
watery or looser-than-normal stools within a 24-hour pe-
riod and/or at least 1 episode of forceful vomiting. The
laboratory criterion was rotavirus antigen detection by
enzyme immunoassay in a stool specimen taken within 14
days of onset of symptoms. Rotavirus antigen in stools was
identified using an enzyme immunoassay. The presence of
wild-type rotavirus was confirmed and the serotype iden-
tified using a one-step reverse transcriptase polymerase
chain reaction assay and negative results on plaque assay
as confirmation.5
Each hospital admission and ED visit was counted as a
separate event if the ED visit occurred 2 or more days
before the hospital admission. If these events occurred
within 2 days, the health care contacts were counted as
a single hospitalization. The definition of a hospitalization
was consistent across regions. However, administration of
emergency care and routine care occurred at a wide
variety of facilities. Therefore, before the study began
in each region, the facilities at which emergency care
and routine care were given were identified and visits to
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these facilities were prespecified as ED and office visits,
respectively. In Finland, for example, children with acute
gastroenteritis requiring emergency care are likely to be
treated in designated Finnish Health Care Centers or Non-
routine Hospital Outpatient Clinics. Thus, visits to facilities
designated as “Finnish Health Care Center Emergency” or
“Nonroutine Hospital Outpatient Clinic Visit” in Finland or
“Outpatient Clinic for Emergency” and “Visit to Hospital”
in Sweden were considered equivalent to an ED visit. “Of-
fice visits” in REST included visits to a health care provider
in a physician' s office, Finnish Health Care Center for
nonemergencies, the study clinic, or other private clinics,
and urgent care centers.
In this post-hoc analysis, the rates of health care
encounters were expressed as the annual number of en-
counters per 1000 person-years because the duration of
follow up differed among subjects. Poisson regression was
used to compare the rates of health care encounters in
the vaccine and placebo groups utilizing generalized es-
timating equations to adjust the standard errors in the
overall per-protocol population.6,7 Generalized estimating
equations are robust to violations of the underlying as-
sumptions of the Poisson model but may not be optimal in
small samples. Thus, the exact binomial method for ratios
of Poisson counts was used to estimate the confidence
intervals for the subgroup analyses by region, given the
number of rotavirus-related health care encounters within
each region.8
Analyses were based on the per-protocol population
with use of the protocol case definition, which was the
occurrence of G1---G4 rotavirus gastroenteritis 14 or more
days following the third dose. Subjects were excluded from
the analyses if protocol violations occurred, no follow-up
occurred 14 days after the third dose, or if the subject was
regarded as not evaluable. Subjects were classified as not
evaluable if a stool specimen was positive for wild-type ro-
tavirus prior to 14 days post dose 3, if they had incomplete
clinical and/or laboratory results, or if stool samples were
collected outside of the 14-day range after symptom onset.
Results
Subjects
In total, data for 69 274 randomly assigned subjects were
available in the clinical database. Among the 68 038 sub-
jects who received at least 1 dose of vaccine, 14% (n =
9518) were excluded because of protocol violations (555
subjects encountered temperature excursions among ad-
ministered vials, 8773 subjects received fewer than 3 vac-
cinations, 43 subjects were cross-treated or prematurely
unblinded, and 147 subjects experienced a combination
of these reasons), 2% (n = 1335) were excluded because
they were not evaluable (i.e., incomplete clinical and/or
laboratory results or stool specimens collected out of day
range), and 0.07% (n = 51) of subjects were excluded be-
cause they did not have follow up beyond 14 days following
dose 3 (Table 1).*
* This reflects the data available for analysis of the health care
resource utilization endpoints in REST.
There were 57 134 subjects who contributed to this
overall per-protocol analysis of hospitalizations and ED
visits (Table 1). By region, 49% (n = 28 002) of the evaluable
subjects were from Europe, 43% (n = 24 463) were from
the United States, and 8% (n = 4489) were from the Latin
American/Caribbean countries. As indicated earlier, there
were an additional 189 subjects from Taiwan who were
excluded from this analysis.
In the efficacy subset, 5673 subjects received at least
1 dose of vaccine. Of these subjects, 10% (n = 566) were
excluded because of protocol violations, 11% (n = 639)
were considered not evaluable, and 0.2% (n = 17) were
excluded because of insufficient follow up. By region, 51%
of the evaluable subjects (n = 2271) were from Finland,
41% (n = 1815) were from the United States, and 8% (n =
365) were from Puerto Rico.
Urgent health care encounters
In the overall cohort, the reduction in the rate of hospi-
talizations and ED visits was 94.4% (95% CI: 90.9, 96.6) for
those with a maximum of 1 year of follow up. Among the
2502 evaluable subjects with more than 1 year of follow
up, the reduction in the rate of hospitalizations and ED
visits was 96.7% (95% CI: 82.1, 99.9).
In the overall per-protocol analysis, 314 of the 28 488
evaluable placebo recipients (1.1%) reported at least one
hospitalization or ED visit for rotavirus gastroenteritis,
and a total of 369 such encounters combined occurred
among the placebo recipients (Table 2). The number and
percentage of subjects reporting at least 1 hospitalization
or ED visit for rotavirus gastroenteritis and the rate of such
urgent health care encounters varied greatly by region.
In Europe, 257 of the 13 984 placebo recipients (1.8%) re-
ported 301 urgent health care encounters (rate of 32.0 per
1000 person-years.) In the United States, 51 of the 12 179
placebo recipients (0.4%) reported 58 urgent health care
encounters (rate of 8.0 per 1000 person-years), whereas,
in the Latin American/Caribbean region, 9 of the 2237
placebo recipients (0.4%) reported 10 urgent health care
encounters (rate of 8.0 per 1000 person-years).
Despite the high variation in rates of health care re-
source utilization for rotavirus gastroenteritis, vaccination
with PRV reduced the rates of hospitalizations and ED visits
combined uniformly across the 3 regions (Table 2). The
reduction in rotavirus-associated hospitalizations and ED
visits was 94.7% (95% CI: 90.9, 96.9) in Europe, 94.9% (95%
CI: 84.0, 98.9) in the United States, and 90% (95% CI: 29.4,
99.8) in the Latin American/Caribbean region.
Nonurgent health care encounters
The reductions in the rate of office visits for rotavirus
gastroenteritis in the efficacy subset in Finland and the
United States were similar (Table 3). The reduction in the
rate of office visits for rotavirus gastroenteritis was 87.2%
(95% CI: 67.5, 94.7) in Finland. In the United States, the
reduction was 84.2% (95% CI: 66.2, 95.1). There were no
office visits reported in Puerto Rico.
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Table 1 Patient disposition by region
Number of subjects (%) in
Region Analysis of urgent health care encounters Analysis of office visits
Vaccine Placebo Vaccine Placebo
Overall a
Number receiving ≥1 dose 34 035 34 003 2834 2 839
Excluded
Protocol violations 4 740 (13.9) 4 778 (14.1) 295 (10.4) 271 (9.5)
Not evaluable 623 (1.8) 712 (2.1) 355 (12.5) 284 (10.0)
Lost to follow-up 26 (0.1) 25 (0.1) 11 (0.4) 6 (0.3)
Evaluable 28 646 (84.2) 28 488 (83.7) 2 173 (76.7) 2 278 (80.2)
Europe Finland
Number receiving ≥1 dose 15 057 15 018 1344 1342
Excluded
Protocol violations 790 (5.2) 756 (5.0) 75 (5.6) 66 (4.9)
Not evaluable 247 (1.6) 274 (1.8) 168 (12.5) 103 (7.7)
Lost to follow-up 2 (0.1) 4 (0.1) 1 (0.1) 2 (0.1)
Evaluable 14 018 (93.1) 13 984 (93.1) 1 100 (81.8) 1 171 (87.3)
United States
Number receiving ≥1 dose 16 170 16 178 1274 1279
Excluded
Protocol violations 3 530 (21.8) 3 597 (22.2) 207 (16.2) 182 (14.2)
Not evaluable 341 (2.1) 385 (2.4) 175 (13.7) 171 (13.4)
Lost to follow-up 15 (0.1) 17 (0.1) 2 (0.2) 1 (0.1)
Evaluable 12 284 (76.0) 12 179 (75.3) 890 (69.9) 925 (72.3)
Latin America/Caribbean (including Puerto Rico)
Number receiving ≥1 dose 2 713 2 713 216 218
Excluded
Protocol violations 418 (15.4) 423 (15.6) 13 (6.0) 23 (10.5)
Not evaluable 34 (1.3) 49 (1.8) 12 (5.6) 10 (4.6)
Lost to follow-up 9 (0.3) 4 (0.1) 8 (3.7) 3 (1.4)
Evaluable 2 252 (83.0) 2 237 (82.5) 183 (84.7) 182 (83.5)
a Includes data from 189 subjects from Taiwan, which were not included in the regional analysis. Nine subjects were excluded from
this country (4 protocol violations, 5 not evaluable).
Discussion
In REST, the efficacy of PRV against rotavirus gastroenteri-
tis caused by serotypes G1---G4 during the first full rotavirus
season after vaccination was 98% against severe disease
and 74% against disease of any grade of severity. These
favorable results translated into significant reductions in
rotavirus-associated health care encounters, including a
94.5% reduction in hospitalizations and ED visits and an
86.0% reduction in office visits in the first 2 years after
vaccination.3 Our subsequent analyses showed that the
rate reductions in the first and second year after vac-
cination were high and consistent, with a reduction in
the rate of hospitalizations and ED visits of 94.4% (95%
CI: 90.9, 96.6) for those with a maximum of 1 year of
follow up and 96.7% (95% CI: 82.1, 99.9) among the 2502
evaluable subjects with more than 1 year of follow up.
Despite the relatively smaller sample size of this subset
of subjects with more than 1 year of follow up, the 95%
confidence interval for the point estimate was relatively
narrow (i.e., 95% CI: 82.1, 99.9), suggesting a robust and
reliable result.
Our analysis extends the results of the original study
of the overall cohort by evaluating the efficacy against
health care encounters by region. Results from each region
were consistent with those of the overall population, with
reductions in the combined endpoint of hospitalizations
and ED visits of 94.7% in Europe, 94.9% in the United
States, and 90.0% in Latin America/the Caribbean.
The efficacy of the vaccine was consistent with the
protection observed following natural infection. In a co-
hort study of 200 infants from Mexico, Velázquez and
colleagues2 determined that protection against severe
disease was afforded following multiple infections. The
adjusted efficacy in protecting against rotavirus-associated
diarrhea was 77% after 1 infection, 83% after 2 infections,
and 92% after 3 infections. These results provided a basis
for vaccine development, suggesting that similar protec-
tion would be anticipated following multiple doses of a
multivalent vaccine.
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Table 2 Efficacy of pentavalent rotavirus vaccine (PRV) against hospitalizations and emergency department visits for
rotavirus gastroenteritis by region
Type of health care encounter within each region Number (rate a) of % Rate reduction 95% CI
health care encounters
Vaccine Placebo
Overall b (N = 28 646) (N = 28 488)
Hospitalizations 6 (0.3) 144 (8.0) 95.8 90.5, 98.2
ED Visits 14 (0.8) 225 (12.6) 93.7 88.8, 96.5
Combined 20 (1.1) 369 (20.6) 94.5 91.2, 96.6
Europe (n = 14 018) (n = 13 984)
Hospitalizations 5 (0.5) 126 (13.4) 96.0 90.3, 98.4
ED Visits 11 (1.2) 175 (18.6) 93.7 87.8, 96.8
Combined 16 (1.7) 301 (32.0) 94.7 90.9, 96.9
United States (n = 12 284) (n = 12 179)
Hospitalizations 0 (0.0) 16 (2.2) 100.0 73.8, 100.0
ED Visits 3 (0.4) 42 (5.8) 92.9 77.4, 98.6
Combined 3 (0.4) 58 (8.0) 94.9 84.0, 98.9
Latin America/Caribbean (including Puerto Rico) (n = 2252) (n = 2237)
Hospitalizations 1 (0.8) 2 (1.6) 50.2 <0.0, 99.1
ED Visits 0 (0.0) 8 (6.4) 100.0 41.2, 100.0
Combined 1 (0.8) 10 (8.0) 90.0 29.4, 99.8
Combined = hospitalizations and emergency department (ED) visits.
a The rates of events represent the incidence density and are expressed as the annual number of events per 1000 person-years.
b Includes data from 189 subjects from Taiwan that were not included in regional analysis.
Table 3 Efficacy of pentavalent rotavirus vaccine (PRV) against office visits for rotavirus gastroenteritis by region in the
efficacy subset
Vaccine Placebo % Rate Reduction 95% CI
Overall Cohort
Number of subjects contributing to the analysis 2173 2278
Number of health care encounters 13 98
Rate (encounters per 1000 person-years) 5.5 39.7 86.0 73.9, 92.5
Finland
Number of subjects contributing to the analysis 1100 1171
Number of health care encounters 7 58
Rate (encounters per 1000 person-years) 4.7 37.0 87.2 67.5, 94.7
United States
Number of subjects contributing to the analysis 890 925
Number of health care encounters 6 40
Rate (encounters per 1000 person-years) 0.8 53.5 84.2 66.2, 95.1
Puerto Rico
Number of subjects contributing to the analysis 183 182
Number of health care encounters 0 0
Rate (encounters per 1000 person-years) 0 0 NA NA
Unlike the consistency of the regional results with PRV
presented here, the previous rhesus-based rotavirus vac-
cine was somewhat less efficacious in Latin America9,10
than in the United States11 or Finland.12
Our analysis did find that the rates of health care
encounters among placebo recipients varied by region. A
number of factors may have contributed to these regional
differences. First, the rates of health care encounters
likely varied in part because of differences in treatment
practice patterns in the different regions. Variations in
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treatment practice patterns by geographic region have
been well documented. Patients in different geographic ar-
eas with illness of similar severities may receive markedly
different care.13 For rotavirus gastroenteritis, variations
in treatment practice patterns may affect the likelihood
of admission to a hospital or visits to other health care
providers. These differences in practice patterns are re-
flected in previous epidemiologic studies. These studies
estimated that by 5 years of age, 1 in 54 children in Europe
overall, 1 in 33 in Finland, and 1 in 70 in the United States
are hospitalized for rotavirus.14- 16 Other potential reasons
for the differences in the rates of health care utilization
by region include differences in the level of care and
patient education provided in a controlled clinical trial,
differences in compliance with the protocol such as differ-
ences between regions in submission of stool specimens for
testing, and the greater frequency of telephone contacts
for subjects participating in the efficacy subset compared
with other subjects. In evaluating the reasons for the
differences in rates of health care utilization, however, it
is important to bear in mind that REST was a randomized,
placebo-controlled study, the purpose of which was to
compare the rate of rotavirus-associated health care en-
counters in the vaccine versus placebo groups. Therefore,
randomization utilizing blocking factors ensured near equal
distribution of vaccine and placebo recipients in a given
region. Thus, the study was designed to account for dif-
ferences in health care practices that might be observed.
As the regional analyses show, the efficacy and reduction
in rotavirus-associated health care encounters is the same
despite the observed differences in disease rates across
regions.
Our results demonstrated high and consistent reduc-
tions in health care encounters regardless of geographic
region or different health care practices. The present
results suggest that PRV will likely be effective against
rotavirus-associated hospitalizations, other urgent visits,
and office visits among children throughout the world. The
greatest expected challenge will be in developing world
populations where children are malnourished, immunocom-
promised, and have intestinal colonization with a variety
of pathogens, where previous candidate rotavirus vaccines
have not been efficacious.17,18 Studies of PRV in Africa and
Asia are expected to begin in the near future.
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